Brookfield Corp’s CureVac CVAC Stock Holding History

Brookfield Corp’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-14,918	Closed	-$512K	–	656
2021 Q4	$512K	Buy	14,918 +8,957	+150%	+$360K	﹤0.01%	539
2021 Q3	$326K	Buy	+5,961	New	+$359K	﹤0.01%	486

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Brookfield Corp's CVAC Position: Q1 2022 in Review

Brookfield Corp sold out of CureVac (CVAC) in Q1 2022, closing a stake of 14,918 shares — an estimated $512K sold.

Brookfield Corp first reported a position in CVAC in Q3 2021 and held it in 2 quarters. The position peaked at $512K in Q4 2021. 111 funds tracked by Wall St. Rank hold CVAC as of Q1 2022.

Brookfield Corp reported no remaining CureVac position as of Q1 2022 after selling out during the quarter.
Brookfield Corp sold 14,918 CureVac shares in Q1 2022, an estimated $512K.
Brookfield Corp first reported a position in CureVac in Q3 2021 and held it in 2 quarters.
Brookfield Corp's CureVac position peaked at $512K in Q4 2021.
111 funds tracked by Wall St. Rank held CureVac as of Q1 2022.

Based on Brookfield Corp's 13F filing for Q1 2022, filed 16 May 2022.